Blow For Industry As GSK-Teva ‘Skinny Label’ Decision Upheld

Split Ruling Plays Down Label Aspects As Appeals Court Backs Coreg Damages

 
• By Dave Wallace

A controversial ruling revolving around labelling carve-outs that saw Teva hit with $235m in damages over its generic rival to GSK’s Coreg has been upheld after being reheard by the US Court of Appeals for the Federal Circuit. However, the court sought to counter the suggestion that its decision upends the Hatch-Waxman framework’s labelling carve-out provisions.

Chisel Carve Out Wood
Labelling carve-outs are once again in the spotlight in the US • Source: Alamy

Labelling carve-outs of patented indications are once again at the heart of legal controversy in the US, after a split 2-1 appeals court for the second time backed a decision to impose fines of $235m on Teva for inducing infringement of patented indications for GlaxoSmithKline’s Coreg (carvedilol) antihypertensive with its generic version, despite these indications being carved out of Teva’s label.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Generics Bulletin